Apple’s next-generation smartwatch lineup is on track for a September debut alongside the iPhone 18 Pro, iPhone 18 Pro Max, and a new iPhone Ultra model. According to fresh Bloomberg reporting, the Apple Watch Series 11 and Apple Watch Ultra 3 will retain a familiar look, walking back earlier speculation that the Ultra line in particular was headed for a more substantial visual overhaul.
Cautious Hardware Refinements
Instead of a dramatic external redesign, Apple is said to be prioritizing two internal upgrades this cycle. The wearables will reportedly gain an all-new System in Package (SiP), marking the first processor architecture change since the Apple Watch Series 9 and promising a meaningful performance uplift. Whether the new chip delivers enough efficiency to push the standard Apple Watch beyond its traditional one-day battery life remains an open question. More aggressive changes are now penciled in for next year’s Apple Watch Series 13, which is expected to debut an entirely new design and a more energy-efficient HMO-OLED display.
A Focus on Health Sensing
Health and fitness tracking remains the centerpiece of the product’s evolution. The most ambitious upgrade on Apple’s roadmap is noninvasive blood glucose monitoring, a feature the company has been pursuing for over a decade. The technology would operate continuously like a traditional continuous glucose monitor, but without needles or disposable sensors. Bloomberg reports that the first Apple Watch capable of reading blood sugar is likely to arrive within this decade, though the timeline remains broad — possibly as early as next year or as late as 2029. It is also unclear whether the initial implementation will provide precise numerical readings or follow a simpler alert-only model, similar to Apple’s existing approach to high blood pressure detection where the device flags elevated or depressed levels rather than displaying exact numbers.
Looking Toward 2026 and Beyond
While consumers hoping for a fresh exterior will need to wait for the Series 13 generation, the near-term hardware strategy points toward a steady, sensor-driven maturation of the platform. Apple’s careful pacing underscores the technical hurdles of reliable noninvasive sensing and the company’s preference for launching health features only when the underlying data quality meets a clinically meaningful bar. In parallel, competitors in the wearable space continue to push display and battery boundaries, setting the stage for a more visibly reimagined Apple Watch when the HMO-OLED transition arrives.
Sources: www.bloomberg.com, unsplash.com